



Final Appraisal Recommendation

Advice number: 0223 – April 2023

**Levodopa-carbidopa-entacapone (Lecigon®) 20 mg/ml +
5 mg/ml + 20 mg/ml intestinal gel**

Submission by Britannia Pharmaceuticals Ltd

This product is not currently marketed in the UK

Recommendation of the All Wales Medicines Strategy Group

Levodopa-carbidopa-entacapone (Lecigon®) is recommended as an option for restricted use within NHS Wales.

Levodopa-carbidopa-entacapone (Lecigon®) is licensed for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.

Levodopa-carbidopa-entacapone (Lecigon®) is restricted within the licensed indication for patients who are not eligible for deep brain stimulation.

Levodopa-carbidopa-entacapone (Lecigon®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- **AWMSG considered levodopa-carbidopa-entacapone (Lecigon®) as an orphan-equivalent medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.**



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4871), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
0223:

Levodopa-carbidopa-entacapone (Lecigon®) 20 mg/ml + 5 mg/ml +
20 mg/ml intestinal gel April 2023